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Abstract 
Introduction: The influence of growth hormone (GH) treatment on amino acids (AAs) profile in patients with Turner syndrome (TS) was 
investigated. 
material and methods: The study group included girls with TS: treated with GH (GH+) and girls with no GH treatment (GH−). The 
control group consisted of healthy girls. Free plasma AAs were measured by the LC/MS/MS.
results: The plasma concentrations of glutamine, threonine were significantly higher in group GH+ than in group GH− (p < 0.05). In 
group GH− the values of glutamine, alanine, isoleucine, glutamic acid were significantly different than in the control (p < 0.05–p < 0.008). 
conclusion: AAs profile in girls with TS might be characteristic for the disease but also depends on GH treatment. (Endokrynol Pol 2021; 
72 (1): 51–52)
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Introduction
Turner syndrome (TS) is the most common chromo-
somal disorder causing short stature in females. Patients 
with TS, although they do not have growth hormone 
deficiency, are commonly treated with recombinant 
human growth hormone (GH) to improve their final 
height [1]. There are conflicting data in literature regard-
ing the impact of GH replacement therapy on changes 
in plasma amino acids (AAs) concentration [2–4] and 
there are no published studies investigating AAs levels 
during growth hormone therapy in girls with TS. It is 
not known if GH therapy, which is important for proper 
protein anabolism, causes changes in free AAs levels in 
girls with TS. Therefore, the aim of this study was to 
assess the influence of GH treatment on amino acids 
profile in patients with TS.
Material and methods
Thirty-six girls with Turner syndrome [17 with X chromosome mono-
somy (45,X), 6 with abnormal X chromosome and 13 with mosaicism] 
were selected for the study group. 28 of them were receiving growth 
hormone therapy (group GH+) and 8 of them were not receiving 
growth hormone therapy (group GH–). The control group consisted 
of 18 girls with normal stature and no metabolic diseases. 
Free plasma AAs were measured by the LC/MS/MS (Agilent Technolo-
gies, Jasem). Glucose, total cholesterol and triglycerides concentra-
tions were measured by dry chemistry analyser (Vitros 4600, Ortho 
Clinical Diagnostics Inc., Rochester, NY, USA). Insulin-like growth 
factor 1 (IGF1) concentrations were measured in serum samples with 
radioimmunoassay method (DIAsource SM-C-RIA-CT Kit, Belgium). 
The questionnaire and methodology for this study was approved 
by the Jagiellonian University Bioethics Committee (Protocol 
No.122.6120.35.2016). 
Results
Fasting serum concentrations of glucose, total cho-
lesterol, triglycerides and amino acids: aspartic acid, 
glycine, taurine, citrulline, arginine, proline, tyrosine, 
valine, leucine levels in group GH+, group GH− and 
in the control did not differ significantly. 
The statistically significant differences in the mean 
values of IGF1, glutamic acid, serine, asparagine, gluta-
mine, histidine, threonine, alanine, methionine, isoleu-
cine, phenylalanine, tryptophan, ornithine and lysine 
between group GH+, group GH− and the control are 
summarized in Table 1.
Discussion
Treatment with GH has been established to be effective for 
increasing final stature in patients with TS. The anabolic 
action of GH may involve redistribution of nitrogen from 
ureagenesis to the extrahepatic anabolic process, together 
with stimulation of AAs uptake and protein synthesis in 
the muscles [5]. Höybye et al. [4] demonstrated higher 
levels of glutamic acid and aspartic acid in adults GH de-
ficiency patients than in the control, but only for glutamic 
acid this difference was significant. GH treatment tended 
to decrease the levels of these AAs towards the levels in the 
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Conclusions
Amino acids profile in girls with Turner syndrome might 
be characteristic for the disease but also depends on GH 
treatment. The combined use of GH treatment and oral 
administration of amino acids may improve metabolism 
in girls with Turner syndrome.
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healthy subjects [4]. Similar results have been obtained in 
the present study, levels of glutamic acid and aspartic acid 
were decreased during GH therapy, but these differences 
for aspartic acid were not statistically significant. Fernholm 
et al. [2] did not find significant changes in plasma AAs 
levels either in males or females after 12 months of GH 
replacement therapy. While Lundeberg et al. [3] showed 
in healthy male volunteers a higher concentration of 
glutamine, alanine and lower levels of valine, leucine and 
histidine in plasma in the growth hormone treated group 
as compared with the initial values. In the previous study 
[6] we found higher concentrations of mean values of 
glutamine and threonine in TS patients with GH therapy 
than in TS patients without GH therapy. That results 
have been confirmed now. Xu et al.[7] demonstrated 
higher serum levels of phenylalanine and tyrosine and 
lower serum levels of serine, lysine, and glutamine in 
the short stature children compared with the healthy 
children. The lower levels of lysine and glutamine are the 
metabolic characterization of the affected growth axes and 
stress state of short stature children, respectively [7]. We 
observed, that the concentrations of glutamine in girls 
with TS normalised upon GH-treatment. Most studies 
demonstrated that growth hormone and glutamine in 
combination exerted synergistic effects in the treatment of 
various diseases e.g. activate the proliferation of crypt cells 
and intestinal stem cells and enhance mucosal growth 
[8]. It is known that oral administration of a specifically 
formulated combination of AAs can increase serum hu-
man growth hormone level [9]. 
table 1. Clinical characteristics and fasting serum concentrations of IGF1, glucose, total cholesterol, triglycerides and fasting 
plasma concentrations of amino acids in the control group and in the study group
Parameter
Turner syndrome Control group  
(n = 18)GH+ (n = 28) GH− (n = 8)
Age [years] 12.5 ± 0.7 9.2 ± 1.3 14.7 ± 0.9
Body mass index [SDS] 0.25 ± 0.17 0.27 ± 0.32 0.24 ± 0.21
IGF1 [ng/mL] 589.6 ± 313.7 p = 0.023b 229.2 ± 87.1 395.1 ± 119.0
Amino acids [µmol/L]
Isoleucine 72.1 ± 3.9 61.1 ± 8.3 p = 0.008a 79.9 ± 11.6
Threonine 132.8 ± 32.1 p < 0.05
b
p = 0.0004a 92.9 ± 16.0 p = 0.0002
a 171.1 ± 39.5
Methionine 20.7 ± 3.9 p = 0.0006a 18.3 ± 1.4 p = 0.0007a 25.9 ± 4.1
Phenylalanine 53.7 ± 8.2 p = 0.0007a 54.9 ± 7.3 p < 0.05a 64.6 ± 8.4
Lysine 180.1 ± 29.3 p = 0.04a 168.2 ± 15.4 p = 0.03a 203.5 ± 26.1
Tryptophan 52.4 (46.1–61.1) p = 0.003a 59.1 (55.7–64.6) 65.4 (62.1–73.1)
Histidine 77.0 ± 9.5 p = 0.002a 72.9 ± 7.2 p = 0.005a 89.8 ± 12.1
Glutamic acid 23.5 (19.3–41.7) 37.1 (30.3–50.9) p = 0.03a 18.3 (13.8–34.0)
Serine 112.9 ± 21.9 p = 0.005a 106.8 ± 22.2 p = 0.03a 138.6 ± 25.0
Asparagine 41.4 ± 7.7 p = 0.03a 38.2 ± 5.4 p = 0.03a 48.6 ± 8.6
Glutamine 640.8 ± 83.5 p = 0.05b 540.4 ± 89.2 p = 0.03a 661.4 ± 72.1
Alanine 356.4 ± 92.7 287.0 ± 69.7 p < 0.05a 379.5 ± 65.4
Ornithine 42.8 ± 9.1 39.8 ± 9.3 p = 0.02a 52.9 ± 9.4
aas compared to control; bas compared to GH– group; to evaluate the distribution of continuous variables in terms of its compliance with the normal distribution, 
the Shapiro-Wilk test was employed. Comparison between groups was performed by using one-way ANOVA test with Tukey unequal N HSD post-hoc test. A p value 
less than 0.05 was considered statistically significant. Statistica software version 10 (StatSoft) was used to perform statistical analysis; Mean value ± SD or Median 
(interquartile range)
